CN1767829A - 作为5－羟色胺再摄取抑制剂的4－(2－苯氧基苯基)－哌啶或－1,2,3,6－四氢吡啶衍生物 - Google Patents

作为5－羟色胺再摄取抑制剂的4－(2－苯氧基苯基)－哌啶或－1,2,3,6－四氢吡啶衍生物 Download PDF

Info

Publication number
CN1767829A
CN1767829A CNA200480008884XA CN200480008884A CN1767829A CN 1767829 A CN1767829 A CN 1767829A CN A200480008884X A CNA200480008884X A CN A200480008884XA CN 200480008884 A CN200480008884 A CN 200480008884A CN 1767829 A CN1767829 A CN 1767829A
Authority
CN
China
Prior art keywords
alkene
base
alkynes
alkane
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480008884XA
Other languages
English (en)
Chinese (zh)
Inventor
B·邦-安德森
F·克罗尔
J·克勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36701494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1767829(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN1767829A publication Critical patent/CN1767829A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CNA200480008884XA 2003-04-04 2004-04-02 作为5－羟色胺再摄取抑制剂的4－(2－苯氧基苯基)－哌啶或－1,2,3,6－四氢吡啶衍生物 Pending CN1767829A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300519 2003-04-04
DKPA200300519 2003-04-04

Publications (1)

Publication Number Publication Date
CN1767829A true CN1767829A (zh) 2006-05-03

Family

ID=36701494

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480008884XA Pending CN1767829A (zh) 2003-04-04 2004-04-02 作为5－羟色胺再摄取抑制剂的4－(2－苯氧基苯基)－哌啶或－1,2,3,6－四氢吡啶衍生物

Country Status (8)

Country Link
KR (1) KR20050119682A (ru)
CN (1) CN1767829A (ru)
AR (1) AR043966A1 (ru)
CL (1) CL2004000726A1 (ru)
EA (1) EA009417B1 (ru)
IS (1) IS7901A (ru)
UA (1) UA81469C2 (ru)
ZA (1) ZA200505031B (ru)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216271A (zh) * 2008-11-14 2011-10-12 施万制药 4-[2-(2-氟苯氧基甲基)苯基]哌啶化合物的结晶型
WO2015090160A1 (zh) * 2013-12-17 2015-06-25 江苏恩华药业股份有限公司 用于制备4-(2‐(4‐甲基苯基硫基))苯基哌啶的化合物、其制备方法及应用
CN105294554A (zh) * 2015-11-18 2016-02-03 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105348204A (zh) * 2015-11-18 2016-02-24 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613347B (zh) * 2008-06-23 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 胺类化合物及其医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241071A (en) * 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
AP2002002481A0 (en) * 1999-10-13 2002-06-30 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors.
UA81749C2 (ru) * 2001-10-04 2008-02-11 Х. Луннбек А/С производные фенилпиперазина как ингибиторы обратного захвата серотонинА

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216271A (zh) * 2008-11-14 2011-10-12 施万制药 4-[2-(2-氟苯氧基甲基)苯基]哌啶化合物的结晶型
CN102216272A (zh) * 2008-11-14 2011-10-12 施万制药 4-[2-(2-氟苯氧基甲基)苯基]哌啶化合物
CN102216271B (zh) * 2008-11-14 2013-09-25 施万制药 4-[2-(2-氟苯氧基甲基)苯基]哌啶化合物的结晶型
CN102216272B (zh) * 2008-11-14 2014-02-05 施万制药 4-[2-(2-氟苯氧基甲基)苯基]哌啶化合物
WO2015090160A1 (zh) * 2013-12-17 2015-06-25 江苏恩华药业股份有限公司 用于制备4-(2‐(4‐甲基苯基硫基))苯基哌啶的化合物、其制备方法及应用
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
CN105294554A (zh) * 2015-11-18 2016-02-03 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105348204A (zh) * 2015-11-18 2016-02-24 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途

Also Published As

Publication number Publication date
UA81469C2 (en) 2008-01-10
IS7901A (is) 2005-06-20
KR20050119682A (ko) 2005-12-21
EA009417B1 (ru) 2007-12-28
ZA200505031B (en) 2006-09-27
EA200501580A1 (ru) 2006-04-28
CL2004000726A1 (es) 2005-05-20
AR043966A1 (es) 2005-08-17

Similar Documents

Publication Publication Date Title
CN1113881C (zh) 8－取代的1,3,8－三氮杂螺[4.5]癸烷－4－酮衍生物
CN1029960C (zh) 具有神经保护作用的苯并二氢吡喃醇衍生物的制备方法
CN1196680C (zh) 新的多巴胺神经传递调节剂
CN1365359A (zh) 苯并呋喃哌嗪和苯并呋喃基高哌嗪:血清素激动剂
CN1882541A (zh) N－[苯基(烷基－2－哌啶基)甲基]苯甲酰胺衍生物,其制备和治疗用途
CN1047385C (zh) 3-吲哚基哌啶和含有它们的药物组合物
CN1325399A (zh) 作为5－ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂草并吲哚
CN101068551A (zh) 喹啉速激肽受体拮抗剂
CN1230432C (zh) 取代的苯基－哌嗪衍生物及其制备和用途
CN1608050A (zh) 哌嗪衍生物
CN1071755C (zh) 杂环甲酰胺衍生物及其作为治疗剂的用途
CN1039996C (zh) N－取代氮杂双环庚烷衍生物及其用途
CN1491223A (zh) 可用于治疗精神性和神经性疾病的3-二氢吲哚衍生物
CN1800145A (zh) 取代的2－二烷基氨基烷基联苯衍生物
CN1095712A (zh) 四氢咔唑衍生物
CN1214048A (zh) 具有白细胞三烯拮抗作用的苯并吡喃衍生物
CN1062349A (zh) 用作药物的3-取代的呱啶类
CN1327976A (zh) 经由新中间体不对称合成苯并噁嗪酮类化合物
CN1606552A (zh) 氨基茚满衍生物作为5－羟色胺和去甲肾上腺素摄取抑制剂
CN1105990A (zh) 苯基链烷醇胺衍生物
CN1161335C (zh) 制备取代的哌啶的方法
CN1153766C (zh) 新的硝酮化合物，其制备方法以及含有它们的药物组合物
CN1767829A (zh) 作为5－羟色胺再摄取抑制剂的4－(2－苯氧基苯基)－哌啶或－1,2,3,6－四氢吡啶衍生物
CN1228082A (zh) 双吲哚基马来酰亚胺的合成
CN1777585A (zh) 作为5－羟色胺再摄取抑制剂的4－(2－苯硫基－苯基)－1,2,3,6－四氢吡啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1089375

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060503

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1089375

Country of ref document: HK